livercancer
-
HLB to Merge with HLB Life Science for Greater Efficiency and ValueBig Tech 2025. 4. 2. 01:53
· HLB merges with HLB Life Science to enhance efficiency and maximize value. HLB has announced its merger with its subsidiary, HLB Life Science, to simplify its corporate structure, enhance management efficiency, and maximize shareholder value. The boards of both companies approved the merger on April 1, with HLB issuing new shares to HLB Life Science shareholders at a predetermined exchange rat..
-
HLB Holds 40th Annual General MeetingBig Tech 2025. 3. 31. 13:30
· Company reaffirms commitment to FDA approval for liver cancer drug On March 31, HLB held its 40th Annual General Meeting (AGM) at the Daejeon Convention Center, followed by an investor relations (IR) briefing and a shareholder meeting. During the AGM, Chairman Jin Yang-gon reaffirmed the company’s commitment to securing U.S. Food and Drug Administration (FDA) approval for its liver cancer drug..
-
US FDA Rejects HLB’s Liver Cancer Drug for the Second TimeBig Tech 2025. 3. 21. 13:40
· FDA issues Complete Response Letter for HLB’s liver cancer drug. The U.S. Food and Drug Administration (FDA) has issued a second Complete Response Letter (CRL) to HLB, a South Korean biopharmaceutical company, regarding its New Drug Application (NDA) for a liver cancer treatment. The decision, announced by HLB Chairman Jin Yang-gon, centers on unresolved issues related to the manufacturing pro..
-
HLB's Liver Cancer Drug Listed as First-Line Treatment in ESMO Guidelines Ahead of FDA ApprovalBig Tech 2025. 2. 27. 12:42
· ESMO strongly recommends rivoceranib and camrelizumab as a first-line treatment for liver cancer. SEOUL, South Korea, February 27, 2025 (IT Times) – HLB announced that its liver cancer treatment, rivoceranib and camrelizumab, has been listed as a first-line treatment in the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis and treatment of hepatocellul..
-
HLB Aims for Three Cancer Drug Approval and Groundbreaking Tumor-Agnostic Therapy by 2025Big Tech 2025. 2. 6. 16:38
· With its liver cancer drug approval decision just a month away, HLB targets breakthroughs in oncology, including a pioneering FGFR2-targeted tumor-agnostic therapy. SEOUL, South Korea, February 6, 2025 (IT Times) - With its liver cancer drug approval decision just a month away, HLB targets breakthroughs in oncology, including a pioneering FGFR2-targeted tumor-agnostic therapy. With just a mont..
-
HLB Completes FDA’s CMC Inspection for Liver Cancer Drug ApprovalBig Tech 2025. 1. 15. 00:18
· Jiangsu Hengrui received three minor improvement requests from the FDA SEOUL, South Korea, January 14, 2025 (IT Times) - HLB, a leading biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has completed the Chemistry, Manufacturing, and Controls (CMC) inspection required for its liver cancer drug approval. The CMC inspection, conducted earlier this month,..